SNCA and Parkinson disease: As already mentioned, MAO-B and Adenosine A2A inhibitors are being studied in the direction of synthesizing new derivatives with more selective and good activity, and other potential Parkinson’s disease treatments targeting α-Synuclein, CK-1δ, Cav 1.3 Calcium channels, and various genetic factors are being announced.